Rezolute, INC Form 4 insider transactions

Rezolute, Inc. Chief Medical Officer Brian Kenneth Roberts sold 3,062 common shares to cover tax withholding obligations related to Restricted Stock Units.

Rezolute Inc. CEO Nevan C. Elam reported a disposition of 8,004 common shares to cover tax withholding obligations related to RSU vesting.

Rezolute Inc. CFO Daron Evans reported a disposition of 3,062 common shares to cover tax withholding obligations related to RSU vesting.

Rezolute, Inc.'s CFO, Daron Evans, reported the direct acquisition of 10,000 common shares at $2.85 per share.

Rezolute's Chief Medical Officer, Brian Kenneth Roberts, disposed of 11,439 common shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

Rezolute Inc.'s CFO, Daron Evans, disposed of 11,438 common shares to cover tax withholding obligations related to Restricted Stock Units vesting.

Rezolute Inc. CEO Nevan C. Elam disposed of 27,618 common shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

A director at Rezolute, Inc. has acquired 5,650 common shares, increasing their beneficial ownership.

Rezolute's Chief Medical Officer, Brian Kenneth Roberts, purchased 28,000 common shares at $1.70 per share, increasing his direct beneficial ownership.

Rezolute, Inc.'s CFO, Daron Evans, increased his direct and indirect holdings in the company through multiple share purchases on December 15, 2025.

Rezolute CEO Nevan C. Elam purchased 32,000 common shares at $1.59 each, increasing direct beneficial ownership to 641,119 shares.

Rezolute's Chief Commercial Officer, Sunil Ratilal Karnawat, acquired 12,100 common shares, signaling strong insider confidence in the company's future.

Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, was granted 123,000 restricted stock units and 72,000 employee stock options.

Rezolute, Inc.'s Chief Commercial Officer, Sunil Ratilal Karnawat, was granted 32,000 restricted stock units and 19,000 employee stock options, effective November 19, 2025.

Rezolute, Inc. CEO Nevan C. Elam received a grant of 317,000 restricted stock units and 186,000 employee stock options, increasing direct beneficial ownership.

Rezolute Inc.'s CFO, Daron Evans, increased his beneficial ownership through the acquisition of 107,000 restricted stock units and 63,000 employee stock options.

Rezolute, Inc. Director Nerissa Kreher acquired 21,000 common shares via restricted stock units and 12,000 stock options on November 19, 2025.

Rezolute, Inc. Director Wladimir Hogenhuis reported the acquisition of 21,000 common shares as restricted stock units and 12,000 stock options, both vesting on December 1, 2026.

Rezolute, Inc. Director Erik Harris was granted 21,000 restricted stock units and 12,000 stock options on November 19, 2025.

Rezolute Director Young-Jin Kim reported acquiring 21,000 restricted stock units and 12,000 stock options.

Rezolute, Inc. Director Philippe Fauchet acquired 21,000 restricted stock units and 12,000 stock options, vesting December 1, 2026.

Rezolute, Inc. Director Gil M. Labrucherie reported acquiring 21,000 restricted stock units and 12,000 stock options.

Rezolute's Chief Commercial Officer, Sunil Karnawat, received grants of 25,000 restricted stock units and 275,000 employee stock options.

Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, acquired 2,500 common shares in the company, signaling increased insider confidence.

Rezolute, Inc.'s Chief Financial Officer, Daron Evans, reported the purchase of 5,000 common shares at $4.05 per share, increasing his direct and indirect beneficial ownership in the company.

A director of Rezolute, Inc. has reported a substantial acquisition of common shares totaling over $4 million, signaling strong insider confidence.

Rezolute, Inc. Director Nerissa Kreher has reported the purchase of 3,076 common shares at $3.25 per share, increasing her direct beneficial ownership to 37,576 shares.

Rezolute, Inc. Director Nerissa Kreher has reported the acquisition of 9,000 common shares as restricted stock units and 5,000 stock options, aligning her interests further with the company.

Rezolute, Inc. Director Gil M. Labrucherie was granted 9,000 restricted stock units and 5,000 stock options, aligning his interests with shareholders.

Rezolute, Inc. Director Wladimir Hogenhuis was granted 9,000 restricted stock units and 5,000 stock options, aligning his interests with shareholders.